DraxImage, the radiopharmaceutical division of Draxis Health, said that it has established a research collaboration agreement with Swiss-based biotechnology firm Med Discovery. The companies said they will explore the combination of Med Discovery's targeted protein therapeutics with DraxImage's radiopharmaceutical products in the therapeutic and diagnostics field.
Med Discovery's lead proteins are potential therapeutic agents for prostate cancer and a variety of other cancers, according to the Montreal-based DraxImage. The collaboration provides initially for the radiolabeling of certain Med Discovery's proteins by DraxImage to assess the enhancement of their therapeutic action and their capability to detect microtumors.
The proteins will be produced at Med Discovery in Switzerland and radiolabeled by DraxImage in Canada, the companies said.